Background and objectives: Surgery is the primary therapy for localized gastric cancer, but even with the best results only 40% 5-year survival can be achieved with the use of postoperative adjuvant chemoradiotherapy. Preoperative therapy might help increase the R0 resection rate, which is an independent predictor of 5-year OS. Our study hypothesized that the concurrent combination of carboplatin-paclitaxel with radiation therapy would result in a pathological CR rate, which will be in turn associated with OAS and DFS benefits. Patients and methods: prospective phase II study included 32 patients with locally advanced gastric adenocarcinoma including gastroesophageal junction who received a combination of neoadjuvant conformal radiotherapy concurrently with carboplatin-paclitaxel followed by surgery. Results: Pathological CR and R0 resection rates were 18.8% and 75% respectively. With a median follow up of 24 months, 2 years disease-free survival was 28.1% and overall survival was 51.3%. The regimen was tolerated with neither grade 4 toxicities nor deaths. Conclusion: Neoadjuvant radiotherapy concomitant with carboplatin-paclitaxel chemotherapy is a well-tolerated approach for patients with locally advanced gastric adenocarcinoma resulting in significant pathological CR and R0 resection margins as reflected by the good DFS and OS.

Breast cancer is the commonest malignant neoplasms among females in worldwide including Egypt. The study was carried out on 1070 out of a total of 1370 patients (78%) presenting with palpable breast lumps diagnosed with neoplastic breast lesions. Approximately one-third of the breast cancer patients diagnosed at age 40–50 years (median age range 49 (26-86 years); 71% came from rural areas; Positive family history was recorded in 7.5%. The patient herself detected the lump in the majority of cases (84%), only 40% sought medical advice with a specialist within the first four months. Accordingly, 62% of these patients presented in advanced stages (III and IV). The main histological type was the invasive ductal carcinoma, in which pathological changes of grade II and III were observed in 62.2% and 24.7% respectively. Conclusion: These findings of this study justify increasing efforts for establishing a comprehensive breast cancer control programs in Egypt for increasing awareness of the breast cancer and the controlling mechanisms as well as advocating for appropriate policies and programs for cancer control and early detection.

Breast cancer is the commonest malignant neoplasms among females in worldwide including Egypt. The study was carried out on 1070 out of a total of 1370 patients (78%) presenting with palpable breast lumps diagnosed with neoplastic breast lesions. Approximately one-third of the breast cancer patients diagnosed at age 40–50 years (median age range 49 (26-86 years); 71% came from rural areas; Positive family history was recorded in 7.5%. The patient herself detected the lump in the majority of cases (84%), only 40% sought medical advice with a specialist within the first four months. Accordingly, 62% of these patients presented in advanced stages (III and IV). The main histological type was the invasive ductal carcinoma, in which pathological changes of grade II and III were observed in 62.2% and 24.7% respectively. Conclusion: These findings of this study justify increasing efforts for establishing a comprehensive breast cancer control programs in Egypt for increasing awareness of the breast cancer and the controlling mechanisms as well as advocating for appropriate policies and programs for cancer control and early detection.

Breast cancer is the commonest malignant neoplasms among females in worldwide including Egypt. The study was carried out on 1070 out of a total of 1370 patients (78%) presenting with palpable breast lumps diagnosed with neoplastic breast lesions. Approximately one-third of the breast cancer patients diagnosed at age 40–50 years (median age range 49 (26-86 years); 71% came from rural areas; Positive family history was recorded in 7.5%. The patient herself detected the lump in the majority of cases (84%), only 40% sought medical advice with a specialist within the first four months. Accordingly, 62% of these patients presented in advanced stages (III and IV). The main histological type was the invasive ductal carcinoma, in which pathological changes of grade II and III were observed in 62.2% and 24.7% respectively. Conclusion: These findings of this study justify increasing efforts for establishing a comprehensive breast cancer control programs in Egypt for increasing awareness of the breast cancer and the controlling mechanisms as well as advocating for appropriate policies and programs for cancer control and early detection.

Breast cancer is the commonest malignant neoplasms among females in worldwide including Egypt. The study was carried out on 1070 out of a total of 1370 patients (78%) presenting with palpable breast lumps diagnosed with neoplastic breast lesions. Approximately one-third of the breast cancer patients diagnosed at age 40–50 years (median age range 49 (26-86 years); 71% came from rural areas; Positive family history was recorded in 7.5%. The patient herself detected the lump in the majority of cases (84%), only 40% sought medical advice with a specialist within the first four months. Accordingly, 62% of these patients presented in advanced stages (III and IV). The main histological type was the invasive ductal carcinoma, in which pathological changes of grade II and III were observed in 62.2% and 24.7% respectively. Conclusion: These findings of this study justify increasing efforts for establishing a comprehensive breast cancer control programs in Egypt for increasing awareness of the breast cancer and the controlling mechanisms as well as advocating for appropriate policies and programs for cancer control and early detection.

Purpose: Aim of this prospective, phase III trial was to compare the efficacy and toxicity of intravenous fluorouracil and oral capecitabine when given concurrently with radiation in adjuvant sitting for adenocarcinoma of the stomach after gastrectomy with D2 resection. Patients and Method: The study included 60 patients having histologically proven adenocarcinoma of the stomach or gastroesophageal junction; stage T2-4 N0-3 M0 after gastrectomy with D2 lymph node dissection. Eligible patients were randomly assigned to receive adjuvant radiotherapy concurrently with intravenous fluorouracil [arm A] or oral capecitabine [arm B]. Results: Ten patients cannot complete their whole treatment course because of either progressive [4 patients; 2 arm A and 2 arm B] or G 3 toxicity [1 patient] or refuse to complete their treatment [5 patients; 3 arm A and 2 arm B]. Patients received fluorouracil have significant increase grade 3 or 4 hematological [neutropenia] and gastrointestinal (diarrhoea, anorexia, and vomiting). During a median follow-up period of 24 months, the 2-year disease free and overall survivals in this study were 60% and 63.3%, for groups A and B respectively, while overall survival were 63.3% and 70% for groups A and B respectively without significant differences. Conclusion: Oral capecitabine concurrently with radiation therapy has comparable efficacy and favourable toxicity profile when compared to infusion fluorouracil as postoperative adjuvant therapy for gastric adenocarcinoma.

Purpose: Aim of this prospective, phase III trial was to compare the efficacy and toxicity of intravenous fluorouracil and oral capecitabine when given concurrently with radiation in adjuvant sitting for adenocarcinoma of the stomach after gastrectomy with D2 resection. Patients and Method: The study included 60 patients having histologically proven adenocarcinoma of the stomach or gastroesophageal junction; stage T2-4 N0-3 M0 after gastrectomy with D2 lymph node dissection. Eligible patients were randomly assigned to receive adjuvant radiotherapy concurrently with intravenous fluorouracil [arm A] or oral capecitabine [arm B]. Results: Ten patients cannot complete their whole treatment course because of either progressive [4 patients; 2 arm A and 2 arm B] or G 3 toxicity [1 patient] or refuse to complete their treatment [5 patients; 3 arm A and 2 arm B]. Patients received fluorouracil have significant increase grade 3 or 4 hematological [neutropenia] and gastrointestinal (diarrhoea, anorexia, and vomiting). During a median follow-up period of 24 months, the 2-year disease free and overall survivals in this study were 60% and 63.3%, for groups A and B respectively, while overall survival were 63.3% and 70% for groups A and B respectively without significant differences. Conclusion: Oral capecitabine concurrently with radiation therapy has comparable efficacy and favourable toxicity profile when compared to infusion fluorouracil as postoperative adjuvant therapy for gastric adenocarcinoma.

Purpose: Aim of this prospective, phase III trial was to compare the efficacy and toxicity of intravenous fluorouracil and oral capecitabine when given concurrently with radiation in adjuvant sitting for adenocarcinoma of the stomach after gastrectomy with D2 resection. Patients and Method: The study included 60 patients having histologically proven adenocarcinoma of the stomach or gastroesophageal junction; stage T2-4 N0-3 M0 after gastrectomy with D2 lymph node dissection. Eligible patients were randomly assigned to receive adjuvant radiotherapy concurrently with intravenous fluorouracil [arm A] or oral capecitabine [arm B]. Results: Ten patients cannot complete their whole treatment course because of either progressive [4 patients; 2 arm A and 2 arm B] or G 3 toxicity [1 patient] or refuse to complete their treatment [5 patients; 3 arm A and 2 arm B]. Patients received fluorouracil have significant increase grade 3 or 4 hematological [neutropenia] and gastrointestinal (diarrhoea, anorexia, and vomiting). During a median follow-up period of 24 months, the 2-year disease free and overall survivals in this study were 60% and 63.3%, for groups A and B respectively, while overall survival were 63.3% and 70% for groups A and B respectively without significant differences. Conclusion: Oral capecitabine concurrently with radiation therapy has comparable efficacy and favourable toxicity profile when compared to infusion fluorouracil as postoperative adjuvant therapy for gastric adenocarcinoma.

Purpose: Aim of this prospective, phase III trial was to compare the efficacy and toxicity of intravenous fluorouracil and oral capecitabine when given concurrently with radiation in adjuvant sitting for adenocarcinoma of the stomach after gastrectomy with D2 resection. Patients and Method: The study included 60 patients having histologically proven adenocarcinoma of the stomach or gastroesophageal junction; stage T2-4 N0-3 M0 after gastrectomy with D2 lymph node dissection. Eligible patients were randomly assigned to receive adjuvant radiotherapy concurrently with intravenous fluorouracil [arm A] or oral capecitabine [arm B]. Results: Ten patients cannot complete their whole treatment course because of either progressive [4 patients; 2 arm A and 2 arm B] or G 3 toxicity [1 patient] or refuse to complete their treatment [5 patients; 3 arm A and 2 arm B]. Patients received fluorouracil have significant increase grade 3 or 4 hematological [neutropenia] and gastrointestinal (diarrhoea, anorexia, and vomiting). During a median follow-up period of 24 months, the 2-year disease free and overall survivals in this study were 60% and 63.3%, for groups A and B respectively, while overall survival were 63.3% and 70% for groups A and B respectively without significant differences. Conclusion: Oral capecitabine concurrently with radiation therapy has comparable efficacy and favourable toxicity profile when compared to infusion fluorouracil as postoperative adjuvant therapy for gastric adenocarcinoma.

Purpose: Aim of this prospective, phase III trial was to compare the efficacy and toxicity of intravenous fluorouracil and oral capecitabine when given concurrently with radiation in adjuvant sitting for adenocarcinoma of the stomach after gastrectomy with D2 resection. Patients and Method: The study included 60 patients having histologically proven adenocarcinoma of the stomach or gastroesophageal junction; stage T2-4 N0-3 M0 after gastrectomy with D2 lymph node dissection. Eligible patients were randomly assigned to receive adjuvant radiotherapy concurrently with intravenous fluorouracil [arm A] or oral capecitabine [arm B]. Results: Ten patients cannot complete their whole treatment course because of either progressive [4 patients; 2 arm A and 2 arm B] or G 3 toxicity [1 patient] or refuse to complete their treatment [5 patients; 3 arm A and 2 arm B]. Patients received fluorouracil have significant increase grade 3 or 4 hematological [neutropenia] and gastrointestinal (diarrhoea, anorexia, and vomiting). During a median follow-up period of 24 months, the 2-year disease free and overall survivals in this study were 60% and 63.3%, for groups A and B respectively, while overall survival were 63.3% and 70% for groups A and B respectively without significant differences. Conclusion: Oral capecitabine concurrently with radiation therapy has comparable efficacy and favourable toxicity profile when compared to infusion fluorouracil as postoperative adjuvant therapy for gastric adenocarcinoma.